Psychedelics have the ability to completely transform the mental health care sector as we know it. Mydecine was formed with the goal of discovering, analyzing, and bringing psychedelic and functional chemicals to worldwide markets to aid in the treatment of mental health and addiction. Our clinical trials are mostly focused on psychedelic-assisted psychotherapy for PTSD and nicotine addiction.
We will begin a phase 2b clinical investigation in collaboration with Johns Hopkins University, which will be supervised by Dr. Matthew Johnson. Dr. Johnson is a Psychiatry and Behavioral Sciences professor at Johns Hopkins. He is one of the world's most published scientists on the human impacts of psychedelics, and his work in the behavioral economics of drug use, addiction, and risk behavior is seminal. The proposed research compares MYCO-001 to a structured smoking cessation therapy program in nicotine-dependent adults.
Mydecine will deliver MYCO-001 for Dr. Matthew Johnson's multi-site smoking cessation experiment at Johns Hopkins, NYU, and UAB. This is the first time in over 50 years that the U.S. government has supported a psychedelic medicines study. Supplying our main drug candidate for this study demonstrates Mydecine's leadership in the growing psychedelic-assisted psychotherapy business.
We are about to conduct Phase 2A clinical research on PTSD among veterans, first responders, and front-line employees. Global test sites have been approved at Leiden University, the University of Alberta, the Royal Ottawa Hospital, and Western Ontario University. In addition, we are nearing completion on numerous US locations, including Boston, Los Angeles, and San Francisco.
We are currently providing funding for a large-scale microdose study that is being conducted at Imperial College London and is being co-sponsored by the National Institute for Health Research. Dr. David Erritzoe, a member of our Medical, Scientific and Technology Advisory Board, is leading the research.
At Macquarie University in Australia, we are carrying out microdose research that is the first of its type. Dr. Vince Polito, who is a member of our Medical, Scientific, and Technology Advisory Board, is in charge of directing this continuing study.